베타
임상 레이더 AI
임상시험 NCT06185465은(는) Irrigation Solution, 만성 상처, 압박 손상, 당뇨병성 족부 궤양, 화상에 대해 모집중 상태입니다. 모든 세부 정보를 보려면 임상시험 레이더 카드 뷰와 AI 발견 도구를 확인하거나 여기에서 무엇이든 물어보세요.
하나의 임상시험이 필터 기준과 일치합니다.
카드 뷰

Effectiveness and Safety of Using Prontosan to Treat Bacterial Biofilm

모집중
임상시험 세부 정보는 주로 영어로 제공됩니다. 하지만 임상 레이더 AI가 도와드릴 수 있습니다! '시험 설명하기'를 클릭하여 선택한 언어로 임상시험 정보를 확인하고, 이에 대해 AI와 논의해 보세요.
임상시험 NCT06185465은(는) Irrigation Solution, 만성 상처, 압박 손상, 당뇨병성 족부 궤양, 화상에 대해 알아보는 중재연구입니다. 현재 상태는 모집중이며, 연구는 2024년 1월 3일에 시작되어 60명의 참여자를 모집하고 있습니다. The First Hospital of Jilin University이(가) 진행하며, 2025년 2월 28일까지 완료될 예정입니다. ClinicalTrials.gov의 가장 최근 정보는 2024년 2월 23일에 갱신되었습니다.
간단한 개요
The goal of this prospective, multi-center, randomized, parallel-controlled, open-label clinical study is to evaluate the effectiveness and safety of Prontosan wound irrigation solution comparing with Normal Saline on the removal of wound bacterial biofilm through observing the morphological characteristics and development of bacterial biofilm in chronic wound patients with secondary infections. The main questions it aims to answer are:

  • Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 7th day of treatment in Group A and Group B
  • Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 3rd day of treatment in Group A and Group B .
  • Positive detection rate of bacterial biofilm in group and group B before the first treatment, and on the 3rd and 7th day of treatment, and difference of the positive detection rate of biofilm among the two groups.
  • 4-phase typing of bacterial biofilm detected in Group A, Group B and Group C before the first treatment, and on the 3rd and 7th day of treatment, and the proportion difference of 4-phase typing of biofilm among the two groups.
  • Wound healing rate
  • Skin Infection Rating Scale (SIRS) score.
  • Distribution of inflammatory cells on the wound.
  • Detection rate of bacteria/drug-resistant bacteria on the wound and their correlation with the detection rate of bacterial biofilm.

Participants will be randomized to experimental group or Control group, Prontosan Wound Irrigation Solution or normal saline will be extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution or normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.

공식 제목

Effectiveness and Safety of Using Prontosan Wound Irrigation Solution to Treat Bacterial Biofilm in Chronic Wound Patients With Secondary Infections: a Randomized, Controlled, Open Multicenter Study.

질환/상태
Irrigation Solution만성 상처압박 손상당뇨병성 족부 궤양화상
기타 연구 식별자
  • 2023-075
NCT 번호
실제 연구 시작일
2024-01-03
최신 업데이트 게시
2024-02-23
예상 연구 완료일
2025-02-28
계획된 등록 인원
60
연구종류
중재연구
단계/상
해당 없음
상태
모집중
키워드
Prontosan wound irrigation solution
Prontosan
Chronic wound
Pressure Injury
Burns
Diabetic Foot Ulcer
주요 목적
치료
설계 할당
무작위배정
중재 모델
평행설계
맹검 (마스킹)
단일맹검
시험군 / 개입
참가자 그룹/시험군개입/치료
실험적Prontosan Wound Irrigation Solution rinse
The test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
Prontosan Wound Irrigation Solution
After debridement surgery, the test group is selected according to the randomization number of enrollment. For experimental group, Prontosan Wound Irrigation Solution is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Prontosan wound irrigation solution is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
활성 대조군Normal Saline rinse
For control group, Normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, Normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
생리 식염수
After debridement surgery, the test group is selected according to the randomization number of enrollment. For control group, normal saline is extracted with syringe (Dosage 1-2ml/cm2), and the wound is rinsed 1 cm from the wound. Then, normal saline is used to saturate the gauze, and the gauze is applied to the wound for 15 minutes. After removing the gauze, cover it with oil gauze, then cover it with 8 layers of gauze and wrap it with a bandage.
주요결과변수
결과변수측정값 설명시간 범위
Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 7th day of treatment in Group A and Group B
Difference in scoring the positive rate of bacterial biofilm=the total score of 3 tissues before treatment- the total score of 3 tissues treatment after 7days. To compare the score difference between 2 groups after the difference is calculated.
Day0, Day7
이차결과변수
결과변수측정값 설명시간 범위
Difference in scoring the positive rate of bacterial biofilm before the first treatment and on the 3rd day of treatment in Group A and Group B
Difference in scoring the positive rate of bacterial biofilm=the total score of 3 tissues before treatment- the total score of 3 tissues treatment after 3 days. To compare the score difference between 2 groups after the difference is calculated
Day0, Day3
Positive detection rate of bacterial biofilm in group and group B before the first treatment, and on the 3rd and 7th day of treatment, and difference of the positive detection rate of biofilm among the two groups
If any of the 3 samples is tested positive for the biofilm, the result will be judged positive (+); If no biofilm is detected in the 3 samples, the result will be judged negative (-).
Day0, Day3,Day7
4-phase typing of bacterial biofilm detected in Group A, Group B and Group C before the first treatment, and on the 3rd and 7th day of treatment, and the proportion difference of 4-phase typing of biofilm among the two groups
Typing I: 0 point is scored in case of free bacteria, i.e., dispersed phase of monomer bacteria; Typing II: 0 points are scored in case of bacterial adhesion, i.e., aggregation phase of monomer bacteria; Typing III\&IV: 3 points are scored in case of mature bacterial biofilm, i.e., closed phase of colony bacteria; 3 points are scored in case of spreading of bacterial biofilm, i.e., open phase of colony bacteria.
Day0, Day3,Day7
Wound healing rate
The wound is covered with sterile mesh film before the first treatment, and on the 3rd and 7th day of treatment, the wound area is measured and recorded, and the difference in wound healing rate among the two groups is compared.
Day0, Day3,Day7
Skin Infection Rating Scale (SIRS) score
o Skin Infection Rating Scale (SIRS) scoring is conducted and recorded before the first treatment, and on the 3rd and 7th day of treatment to compare the differences of SIRS scores among the two groups. SIRS scoring Items include Exudate / pus, Scabbing, Erythema/Inflammation, Tissue edema, Tissue fever, Pruritus and Pain. The scores of every items are 0=none, 1=mild, 2= Moderate, 3= severe.
Day0, Day3,Day7
Distribution of inflammatory cells on the wound
The H-E staining pathological sections of inflammatory cells on the wound are carried out before the first treatment, and on the 3rd and 7th day of treatment to compare the differences in the distribution type (Monocytes/Neutrophils/Lymphocytes) and quantity(No infiltration, mild infiltration, moderate infiltration, severe infiltration) of inflammatory cells on the wound among the two groups. mild infiltration refers to the infiltration of less than or equal to 10 inflammatory cells; moderate infiltration refers to the infiltration of 11-50 inflammatory cells; severe infiltration refers to the infiltration of more than 50 inflammatory cells.
Day0, Day3,Day7
Detection rate of bacteria/drug-resistant bacteria on the wound and their correlation with the detection rate of bacterial biofilm
According to the test results, the number of bacteria positive cases and number of drug-resistant positive bacteria cases are counted, and the difference in anti-infection ability of the two groups after 3 and 7 days of wound treatment is compared by the number of positive cases/total number of burn patients in each group and the number of drug-resistant bacteria positive cases/total number of burn patients in each group.
Day0, Day3,Day7
적격성 기준

연령대
성인, 노인
최소 연령
18 Years
참여 가능한 성별
전체
  • 1. Voluntarily sign the informed consent form;
  • 2. ≥18 years old;
  • 3. Patients with chronic wound, eg. burns, and pressure injuries with stage 3 and 4. Diabetes foot ulcer with Wagner grade 2; (Staging and Wagner grading of stress injury can be found in attachments 1 and 2);
  • 4. The length and width of a single wound in the wound area where the sampling point is located must be ≥2 cm, and the maximum length and width must be ≤10 cm;
  • 5. The rapid smear test results of bacteria on the wound were positive;
  • 6. The clinical symptoms of wound infection meet the following conditions: skin infection level scale score (SIRS) ≥ 8;
  • 7. Patients identified by the investigator as having biofilm formation on the wound;
  • 8. No eschar covering the wound surface.

  • 1. Patients administered with systemic antibiotics 48 hours before enrollment;
  • 2. Patients with severe autoimmune diseases;
  • 3. Patients with pressure injuries classified as Stage I and II; (Please refer to Attachment 1 for for pressure injury staging);
  • 4. Diabetes foot ulcer with Wagner grade0- 1 and more than 3; (Wagner grading of stress injury can be found in attachments 2);
  • 5. Female in pregnancy or lactation period;
  • 6. Those who have participated in clinical trials of drugs or devices within one month before the first treatment;
  • 7. Patients who are allergic to any component of the research device;
  • 8. Those who are currently using tumor chemotherapy drugs during screening;
  • 9. Any condition that, in the opinion of the investigator, may increase the risk to the subjects or otherwise affect the evaluation of efficacy.
The First Hospital of Jilin University logoThe First Hospital of Jilin University
연구 대표 연락처
연락처: Jia'ao Yu, Professor, +86 13804337395, [email protected]
연락처: Xinxin Gao, Ph.D., +86 13804337395, [email protected]
3 1개국에 임상시험 장소

Fujian

Fujian Medical University Union Hospital, Fuzhou, Fujian, China
Chenjian Zhong, Ph.D, 연락처
Xintian Zhang, 연락처
대상자모집전

Jilin

First Hospital of Jilin University, Changchun, Jilin, China
Xinxin Gao, Ph.D, 연락처, +86 13804337395, [email protected]
모집중

Shenzhen

Shenzhen Second People's Hospital, Shenzhen, Shenzhen, China
Yating Wei, Ph.D, 연락처
Rong Zhong, 연락처
대상자모집전